Lidocaine 4%
Brand Names: Relaxink Lidocaine, Healthwise Lidocaine Pain Relief, Recovery Numb, Healthwise Lidocaine Patch, Lidocore (Single Unit Patch), Numbsure Lidocaine
Methodology & AI Transparency ⓘ
Lidocaine 4% Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Uses Helps relieve the pain, itching and burning associated with hemorrhoids and other anorectal disorders.
- 2 Real-world patient consensus: Tracked across 21 patient dosage logs with a 77% satisfaction benchmark (RxCUI 1421893).
- 3 Typical cash cost range: Dispensing cost comparison spans $12.50 mail/discount cash up to $34.50 uninsured retail (federal NADAC $0.0989).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Lidocaine 4% include pruritus (4.2%), nausea (8%), headache (6.8%).
Ask our AI Specialists anything about Lidocaine 4%
Lidocaine 4% Mechanism, CYP450 Pathways & DailyMed Monograph
Uses Helps relieve the pain, itching and burning associated with hemorrhoids and other anorectal disorders. Avoid contact with eyes. Do not exceed recommended dosage unless directed by a doctor. Do not put this product into the rectum by using fingers or any mechanical device or applicator. Stop use and ask a doctor if: Rectal bleeding occurs. Condition worsens or does not improve within 7 days. Allergic reaction occurs to ingredients in this product.
As an active amide local anesthetic moiety (Hambli Limited), Lidocaine 4% modulates physiological signaling proportional to 4 g/100g Patch exposure and hepatorenal clearance (SPL 2026-02-15).
Following administration (4 g/100g Patch), Lidocaine 4% achieves Estimated 48%–60% oral systemic absorption for Lidocaine 4% bioavailability and peak plasma concentration (tmax) reached 1–3 hours post-dose for lidocaine 4% onset, governed by a Approximately 6–17 hours terminal plasma half-life for Lidocaine 4% terminal half-life through phase i/ii hepatic conjugation of lidocaine 4% coupled with glomerular and tubular renal excretion.
Before initiating Lidocaine 4% at 4 g/100g Patch, clinical safety checklists rule out severe drug-induced hypersensitivity to lidocaine 4% or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-02-15 for lidocaine 4%. Logged tolerability patterns center on nausea (8% of reports), headache (6.8% of reports), dizziness (6% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Lidocaine 4% (amide local anesthetic).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Lidocaine 4% dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Lidocaine 4% or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-02-15 for Lidocaine 4%
Logged Side-Effect Incidence (21 Reports)
Lidocaine 4% Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lidocaine 4%)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Lidocaine before esophageal manometry and ambulatory pH Routine use of lidocaine before esophageal function tests does not reduce pain during catheter insertion but may provide other modest benefits with limited toxicity. Neurogastroenterology and motility • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33969923 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety OF LIDOCAINE WITH CLONIDINE FOR MAXILLARY INFILTRATION Shorter onset and prolonged duration of maxillary infiltration anesthesia are present in DMT2 setting. The journal of evidence-based dental practice • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40335197 ↗ |
| Can This Approach Help? Inside the Latest Research on Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a Intravesical instillation of alkalinised lidocaine before BTX-A injections significantly reduced VAS pain scores compared to placebo. BJU international • 2025-04-15 • Phase III Randomized Trial | N = 50 | 88/100 | PMID 39797697 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Combined skin-applied Lidocaine and Tetracaine Cream for This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. Journal of cosmetic dermatology • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40735955 ↗ |
| Can This Approach Help? Inside the Latest Research on Use of Remifentanil Associated with Lidocaine for Feticides in Late Terminations The study included 66 women, randomized into 2 groups of similar size and characteristics. Fetal diagnosis and therapy • 2021-01-15 • Phase III Randomized Trial | N = 66 | 82/100 | PMID 34808620 ↗ |
Lidocaine 4% Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0989/unit (~$2.97/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $12.50 / mo | View logs ↓ |
Lidocaine 4% Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lidocaine 4% RxNorm Concept ID | 1421893 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0989 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $12.50 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lidocaine 4% Patient Community, Cohort Filters & Dosage Logs
Deterministic Lidocaine 4% reference combining NIH RxNorm (1421893), Medicaid NADAC ($0.0989/unit), and anonymous cohort outcomes (77% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lidocaine 4% community threads and patient logs by age, biological sex, dosage, and treatment duration.